J Pediatr Gastroenterol Nutr 2021 Jun 1. Epub 2021 Jun 1.
Division of Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
Objectives: Tofacitinib, a selective Janus kinase inhibitor, effectively induces and maintains remission in adults with inflammatory bowel disease (IBD), but data are limited in children. This study aimed to evaluate the efficacy and safety of tofacitinib for medically-refractory pediatric-onset IBD.
Methods: This single-center retrospective study included subjects aged 21 years and younger who started tofacitinib for medically-refractory IBD. Read More